ArticleEuropean thyroid journal2021
Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.
Article in European thyroid journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- The burden of thyroid eye disease: Evaluating treatment outcomes on quality of life.European journal of ophthalmology · 2026Pooled it
- Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.BMJ open ophthalmology · 2024Pooled it
- Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.Endocrine · 2024Trial
- Ocular Hypertension and Glaucoma in Graves' Orbitopathy: A Single-Center Retrospective Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Graves' disease: review of disease characteristics, burden, and treatments.Frontiers in endocrinology · 2026Review
- Predictive factors for surgical interventions following intravenous glucocorticoid pulse therapy in active moderate-to-severe thyroid eye disease.Hormones (Athens, Greece) · 2025Article
- Unravelling the pathogenic mechanisms in Graves' orbitopathy.European thyroid journal · 2025Review
- Teprotumumab Improves Quality of Life in Thyroid Eye Disease: Meta-analysis and Matching-adjusted Indirect Comparison.Journal of the Endocrine Society · 2025Review
- Investigating factors influencing quality of life in thyroid eye disease: insight from machine learning approaches.European thyroid journal · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves' orbitopathy.International ophthalmology · 2024Article
- Safety of non-standard regimen of systemic steroid therapy in patients with Graves' orbitopathy: a single-centre experience.Pharmacological reports : PR · 2024Article
- Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves' orbitopathy.International ophthalmology · 2023Article
- Traditional Chinese medicine in thyroid-associated orbitopathy.Journal of endocrinological investigation · 2023Review
- Measuring Health-Related Quality of Life in Thyroid Eye Disease.The Journal of clinical endocrinology and metabolism · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the predictive factors for changes in the quality of life (GO-QoL) of patients with Graves' orbitopathy (GO) prior to and after specific treatment.
methodsA prospective follow-up study was conducted at an academic tertiary referral orbital center with a joint thyroid-eye clinic on 100 consecutive patients with GO. Before and after the standard 12-week course of weekly intravenous methylprednisolone (cumulative dose 4.5 g), the GO-QoL questionnaire provided by the European Group on Graves' Orbitopathy (EUGOGO) was completed. Endocrine and ophthalmic assessments were performed at each visit.
resultsAll patients were biochemically euthyroid and untreated for GO at baseline and presented with active and moderate-to-severe disease. Both GO-QoL subscales (visual functioning [VF] and appearance [AP]) significantly increased after immunosuppressive therapy and showed a sustained improvement for 6 months. At baseline, demographic variables (sex, age, and smoking) influenced QoL in the stepwise linear regression (
conclusionsPredictive factors for GO-QoL differed not only between the 2 subscales but also before and after the first treatment of GO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.